OSE Immunotherapeutics SA OSE.PA Stock
OSE Immunotherapeutics SA Price Chart
OSE Immunotherapeutics SA OSE.PA Financial and Trading Overview
OSE Immunotherapeutics SA stock price | 4.71 EUR |
Previous Close | 3.46 EUR |
Open | 3.5 EUR |
Bid | N/A x N/A |
Ask | N/A x N/A |
Day's Range | 3.41 - 3.5 EUR |
52 Week Range | 3.33 - 7.8 EUR |
Volume | 8.62K EUR |
Avg. Volume | 32.38K EUR |
Market Cap | 65.37M EUR |
Beta (5Y Monthly) | 1.035632 |
PE Ratio (TTM) | N/A |
EPS (TTM) | -1.18 EUR |
Forward Dividend & Yield | N/A (N/A) |
Ex-Dividend Date | N/A |
1y Target Est | 11.3 EUR |
OSE.PA Valuation Measures
Enterprise Value | 83.19M EUR |
Trailing P/E | N/A |
Forward P/E | -3.913793 |
PEG Ratio (5 yr expected) | N/A |
Price/Sales (ttm) | 3.571771 |
Price/Book (mrq) | 1.9313669 |
Enterprise Value/Revenue | 4.545 |
Enterprise Value/EBITDA | -5.287 |
Trading Information
OSE Immunotherapeutics SA Stock Price History
Beta (5Y Monthly) | 1.035632 |
52-Week Change | -44.89% |
S&P500 52-Week Change | 20.43% |
52 Week High | 7.8 EUR |
52 Week Low | 3.33 EUR |
50-Day Moving Average | 4.1 EUR |
200-Day Moving Average | 5.71 EUR |
OSE.PA Share Statistics
Avg. Volume (3 month) | 32.38K EUR |
Avg. Daily Volume (10-Days) | 28.92K EUR |
Shares Outstanding | 18.95M |
Float | 11.5M |
Short Ratio | N/A |
% Held by Insiders | 39.03% |
% Held by Institutions | 1.71% |
Shares Short | N/A |
Short % of Float | N/A |
Short % of Shares Outstanding | N/A |
Dividends & Splits
Trailing Annual Dividend Rate | 0 |
Trailing Annual Dividend Yield | 0% |
5 Year Average Dividend Yield | N/A |
Payout Ratio | 0 |
Last Split Factor |
Financial Highlights
Fiscal Year
Fiscal Year Ends | December 31, 2022 |
Most Recent Quarter (mrq) | December 31, 2022 |
Next Fiscal Year End | December 31, 2023 |
Profitability
Profit Margin | -97.037% |
Operating Margin (ttm) | -100.95% |
Gross Margin | 100.00% |
EBITDA Margin | -85.96% |
Management Effectiveness
Return on Assets (ttm) | -11.92% |
Return on Equity (ttm) | -44.097% |
Income Statement
Revenue (ttm) | 18.3M EUR |
Revenue Per Share (ttm) | 0.99 EUR |
Quarterly Revenue Growth (yoy) | -87.00000000000000000000000000000000% |
Gross Profit (ttm) | 18.3M EUR |
EBITDA | -15733000 EUR |
Net Income Avi to Common (ttm) | -17760000 EUR |
Diluted EPS (ttm) | -0.39 |
Quarterly Earnings Growth (yoy) | N/A |
Balance Sheet
Total Cash (mrq) | 25.62M EUR |
Total Cash Per Share (mrq) | 1.38 EUR |
Total Debt (mrq) | 44.79M EUR |
Total Debt/Equity (mrq) | 137.16 EUR |
Current Ratio (mrq) | 2.287 |
Book Value Per Share (mrq) | 1.763 |
Cash Flow Statement
Operating Cash Flow (ttm) | -18252000 EUR |
Levered Free Cash Flow (ttm) | -9276125 EUR |
Profile of OSE Immunotherapeutics SA
Country | France |
State | N/A |
City | Nantes |
Address | 22, boulevard Benoni Goulin |
ZIP | 44200 |
Phone | 33 2 28 29 10 10 |
Website | https://www.ose-immuno.com |
Industry | Biotechnology |
Sector(s) | Healthcare |
Full Time Employees | N/A |
OSE Immunotherapeutics SA, a clinical-stage biotechnology company, develops immunotherapies in the areas of immune-oncology and immune-inflammation in France and internationally. Its products include Tedopi that is in Phase III clinical trial for the treatment of non-small cell lung cancer, as well as in Phase II clinical trial to pancreatic and ovarian cancer; OSE-279, which is in a Phase I/II clinical trial in patients with advanced solid tumors or lymphomas; OSE-127, a humanized monoclonal antibody that is in Phase II clinical trial for the treatment of ulcerative colitis, as well as Sjögren's Syndrome; and FR104, which is in Phase I clinical trial for the treatment of rheumatoid arthritis. The company is also developing BI 765063, which is in Phase I clinical trial to treat solid tumors; OSE-230, an agonist antibody against ChemR23 to resolve chronic inflammation; CLEC-1, a therapeutic target in immune-oncology and identified monoclonal antibody antagonists; and BiCKI, a novel bispecific checkpoint inhibitor platform that targets PD-1 to fight primary and secondary resistance mechanisms developed by cancers. OSE Immunotherapeutics SA has collaborations and partnerships with GERCOR, ARCAGY-GINECO, Foundation FoRT, and Nantes University Hospital; and Boehringer Ingelheim, MabSilico, CKD, Servier, Veloxis Pharmaceuticals, and Chong Kun Dang Pharmaceutical Corporation. The company was formerly known as OSE Pharma SA and changed its name to OSE Immunotherapeutics SA in May 2016. OSE Immunotherapeutics SA was founded in 2012 and is headquartered in Nantes, France.
Q&A For OSE Immunotherapeutics SA Stock
What is a current OSE.PA stock price?
OSE Immunotherapeutics SA OSE.PA stock price today per share is 4.71 EUR.
How to purchase OSE Immunotherapeutics SA stock?
You can buy OSE.PA shares on the Paris exchange. Contact your financial advisor to select a broker.
What is the ticker symbol for OSE Immunotherapeutics SA?
The stock symbol or ticker of OSE Immunotherapeutics SA is OSE.PA.
Which industry does the OSE Immunotherapeutics SA company belong to?
The OSE Immunotherapeutics SA industry is Biotechnology.
How many shares does OSE Immunotherapeutics SA have in circulation?
The max supply of OSE Immunotherapeutics SA shares is 21.6M.
What is OSE Immunotherapeutics SA Price to Earnings Ratio (PE Ratio)?
OSE Immunotherapeutics SA PE Ratio is now.
What was OSE Immunotherapeutics SA earnings per share over the trailing 12 months (TTM)?
OSE Immunotherapeutics SA EPS is -1.18 EUR over the trailing 12 months.
Which sector does the OSE Immunotherapeutics SA company belong to?
The OSE Immunotherapeutics SA sector is Healthcare.
OSE Immunotherapeutics SA OSE.PA included in indexes
Name Name | Price Price |
24h% 7d chart 24h% & 7d |
VOL Volume | 24h low | 24h high | Volume |
---|
Name Name | Price Price |
24h% 7d chart 24h% & 7d |
VOL Volume | 24h low | 24h high | Volume | |
---|---|---|---|---|---|---|---|
{{ item.name }} {{ item.symbol }} | {{ item.price }} {{ item.price_usd }} |
{{ item.change_pct }}
|
{{ item.volume }} {{ item.volume_usd }} | {{ item.low }} {{ item.low_usd }} | {{ item.high }} {{ item.high_usd }} | {{ item.components_count }} - | {{ item.volume }} {{ item.volume_usd }} |
CAC Mid & Small MS190 | 14267.59 EUR 15596.4 USD |
-0.38
|
— — | — — | — — | — - | — — |
CAC Small CS90 | 11739.13 EUR 12832.46 USD |
-0.74
|
— — | — — | — — | — - | — — |
- {{ link.label }} {{link}}